Furthermore, KAAD-cyclopamine treatment suppressed the expression of the c-Myc proto-oncogene, a key oncogenic factor in hepatocarcinogenesis and a major regulator of cell proliferation, and inhibited Hep3B cell growth which suggests a role of SMO-mediated upregulation of c-Myc in enhancing HCC growth [68]. This evidence concerns the gene SMO and hepatocellular carcinoma.